Moolec Science to merge with Bioceres Group entities in major bioeconomy deal

Luxembourg-based Moolec Science has announced a major strategic transaction that will see the molecular farming specialist merge with Bioceres Group Limited and affiliated companies Nutrecon and Gentle Technologies Corp in an all-stock deal. The transaction is expected to significantly expand Moolec’s technology platforms and global reach across the agri-food and bioeconomy sectors.

Under the Business Combination Agreement (BCA), signed on 17 April 2025, Moolec will issue up to 87 million new shares and five million warrants to the shareholders of the three contributing entities. The resulting structure will position Moolec as the parent company of a significantly broadened organization with deep expertise across biological inputs, ingredient production, and synthetic biology.

Speaking on behalf of Bioceres Group, Federico Trucco, a board member and CEO of Bioceres Crop Solutions, described the move as a necessary shift to meet future demands in agriculture.

“The need to accelerate agricultural innovation to address current and future challenges, such as enhancing on-farm profitability and reducing environmental impact, is increasingly evident,” Trucco said. “Moolec's transformational transaction represents the kind of bold action needed to drive radical change in agriculture.”

The combined company will aim to deliver sustainable solutions across the value chain, including seed and microbe innovation, on-farm productivity improvements, and health-positive food ingredient development. Moolec, currently listed on NASDAQ under the ticker MLEC, is known for its molecular farming platform that uses genetically modified crops to produce animal proteins such as bovine serum albumin in plants.

Juan Sartori, Founder & Chairman of Union Group, called the merger “the creation of a new kind of company for the 21st century”.

“By combining science, scale, and sustainability, Moolec is positioned to lead a global transformation in how we produce food, materials, and energy,” Sartori said.

The deal brings together a portfolio of over 800 patents and patent applications, as well as more than 550 product registrations. According to recent financial statements, the combined businesses generated over US$500 million in goods and services sold during the last fiscal year, with customers in more than 50 countries.

The transaction is also expected to create operational synergies and expand the company’s addressable markets. José López Lecube, CFO & Director at Moolec, said the integration will bring both financial and strategic benefits.

“Becoming part of a larger organization will enable cost efficiencies and significant revenue increase as well as product portfolio diversification,” López Lecube said. “It will also enlarge our investor base, providing the company with new stakeholders who support Moolec’s new and more diversified business.”

Alejandro Antalich, Chairman of Synbio Powerlabs, underscored the transaction’s implications for the wider bioeconomy.

“By integrating next-gen ingredients, biological ag solutions, and deep-tech manufacturing capabilities under one roof, we are building a company with unmatched scientific depth and commercial reach,” Antalich said.

As part of the restructuring, Moolec CEO Gastón Paladini will step down as Chief Executive Officer, Director, and Chairman of the Board immediately following the company’s Extraordinary General Meeting on 22 April 2025.

The deal is subject to customary closing conditions and shareholder approvals. If completed as expected, it will mark a significant milestone in the evolution of Moolec from a molecular farming startup into a diversified biotechnology platform with broad application in sustainable food, agriculture, and bio-based innovation.